GAITHERSBURG – AstraZeneca said on Monday it will invest $2 billion to expand its manufacturing footprint in Maryland, including a major expansion of its biologics facility in Frederick and construction of a new clinical manufacturing site in Gaithersburg.
The investment will support 2,600 jobs across the two sites, including 300 highly skilled roles, retention of existing positions, and thousands of construction-related jobs. Both facilities are expected to be operational by 2029.
The Frederick site, which produces biologics used in cancer, autoimmune, respiratory and rare disease treatments, will nearly double its commercial manufacturing capacity. The expansion will add 200 highly skilled jobs and 900 construction roles, while enabling production across AstraZeneca’s rare disease portfolio for the first time.
In Gaithersburg, AstraZeneca will build a new state-of-the-art clinical manufacturing facility to support development and supply of innovative molecules for clinical trials. The site will create 100 jobs, retain 400 roles and generate 1,000 construction jobs.
Both facilities will incorporate AI, automation and data analytics, and be built to high environmental standards.
Maryland Governor Wes Moore said the investment underscored the state’s “world-class biotech ecosystem” and would strengthen the U.S. medicine supply chain. AstraZeneca CEO Pascal Soriot called the move a “landmark moment” that deepens the company’s commitment to Maryland and accelerates access to therapies for patients.
The announcement is part of AstraZeneca’s $50 billion global investment plan unveiled in July, which includes new facilities in Virginia and Texas. The U.S. remains AstraZeneca’s largest market, with more than 25,000 employees and 19 R&D, manufacturing and commercial sites.